Purpose

To evaluate the clinical utility associated with the integration of Cxbladder into the evaluation of subjects presenting with hematuria for evaluation of urothelial carcinoma (UC) without compromising detection of UC.

Category

IRB Number
20210674HU
NCT Number
NCT03988309
Open to Enrollment
Yes
Sponsor
Pacific Edge Limited -



Study Contact

Principal Investigator
Robert Svatek

Karl Norton
(210) 450-9630
nortonk1@uthscsa.edu

Brandi Weaver
(210) 567-0158
weaverb@uthscsa.edu



Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

    >
    1. Patient is undergoing investigation of recent confirmed hematuria (by either flexible or rigid cystoscopy/TURBT), including hematuria subjects referred due to suspicious/positive imaging, in order to determine the presence of urothelial carcinoma.
    2. Able to provide a voided urine sample of the required minimum volume
    3. Able to give written consent
    4. Able and willing to comply with study requirements
    5. Aged 18 years or older
    <

Exclusion Criteria

    1. Prior history of bladder malignancy, prostate or renal cell carcinoma
    2. Prior genitourinary manipulation (flexible or rigid cystoscopy / catheterisation, urethral dilation) in the 14 days before urine collection,
    3. History of glomerulonephritis, nephrosis or other renal inflammatory disorders, recent history of pyelonephritis
    4. Previous alkylating based chemotherapy
    5. Pregnancy

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Diagnostic
Masking
None (Open Label)
Condition
  • Hematuria
  • Urothelial Carcinoma
  • Arm Groups

    ArmDescriptionIntervention
    No Intervention

    Control

    Subjects on the control arm will be on standard of care. Trial nomogram clinical risk factor categorization for control arm subjects will not be provided to the physician (but appropriate information will be collected on the CRF to enable sub-group analysis) No Cxbladder test results will be provided for control arm subjects. Note that Cxbladder test results will be available for eventual analysis for these subjects.
    Active Comparator

    Test, subjects categorised as "low risk" or "Not low risk"

    A clinical risk factor nomogram risk classification will be used in this study. The nomogram categorizes subjects as either "low risk" or "not low risk" categories. "Low risk" subjects satisfy all conditions and "not low risk" satisfies at least one of the conditions.The Cxbladder Triage test result will be provided to physicians for all "low risk" subjects on the test arm. If a "low risk" subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the "low risk" subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. Subjects categorised as "not low risk" will be evaluated as per standard of care. Note that Cxbladder test results will be available for eventual analysis for these subjects.
  • Diagnostic Test: Cxbladder

    The Cxbladder Triage test result will be provided to physicians for all "low risk" subjects on the test arm. If a "low risk" subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the "low risk" subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. "Not low risk" patients will be evaluated as per standard of care.